Compare Baker Hughes Co (BKR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs TG Therapeutics Inc — how do they compare? Baker Hughes Co trades at $64.65 (market cap $64.34B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Baker Hughes Co is far larger — about 8.4× TG Therapeutics Inc's market cap, and Baker Hughes Co pays a 1.42% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BKR | TGTX | |
|---|---|---|
Market Cap | $64.34B | $7.64B |
Sector | Energy | Health |
52-Week High | $69.67 | $59.06 |
52-Week Low | $42.51 | $26.94 |
Enterprise Value | $64.86B | $7.84B |
Dividend Yield | 1.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $64.69, up 0.97% today, with strong technical and fundamental momentum. The stock shows bullish moving averages and has beaten earnings estimates for the last three quarters. Recent news includes major contracts for subsea systems and LNG technology, supporting revenue growth. Analyst consensus is strongly positive with a $73.25 price target, indicating ~13% upside from current levels.
Outlook remains favorable driven by energy infrastructure demand and operational execution, though risks include oil price volatility and integration challenges from the Chart acquisition. The stock offers growth potential with solid cash flow and margin expansion, but investors should monitor debt levels and global energy spending trends.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
